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Spontaneous adverse drug reactions (ADRs) reporting is a useful source of drug safety
information in infants as only adult patients are routinely tested in clinical trials. This
study was aimed to evaluate the spontaneously reported ADRs using WHO Adverse
Reaction Terminology and to identify the common drugs associated with ADRs in
children under 2 years of age. A retrospective analysis of ADR data for children below
2 years old from 2000 to 2013 was conducted using the data extracted from Malaysia’s
national pharmacovigilance database, QUEST2 System. From 2000 to 2013, Malaysia’s
National Pharmaceutical Control Bureau received a total of 11,932 reports for children
from various healthcare facilities in Malaysia. 14.0% (n = 1667) of the ADRs reported
for those children were related to children under 2 years old. The data retrieved was
analyzed in terms of age, gender, source of reporting, type of reporters, suspected
medicines and characteristics of ADRs (category, onset, severity, and outcomes). A total
of 1312 ADRs reported in 907 ADR reports were analyzed. The most common ADRs
reported were skin appendage disorders (60.1%), and the most frequently reported
symptoms were rash (n = 215), maculopapular rash (n = 206), urticaria (n = 169),
erythematous rash (n = 76), and pruritus (n = 58). In general, drugs from antibacterials
for systemic use (58.8%) appeared to be the most common contributors to ADRs in
children below 2 years old. Penicillins and other β-Lactam Antibacterials accounted for
more than 40% of all drugs implicated in ADRs. The majority of ADRs were subacute
reactions that occurred within 24 h of exposure to the drug. A high proportion of ADRs
was classified as mild, and most victims had no sequela. Only one fatality was seen.
There were 10 cases for each symptom, namely erythema multiforme and Stevens–
Johnson Syndrome, observed in this study. A large proportion of ADRs in children under
2 years old were mainly caused by drugs from antibacterial for systemic use, with most
of the ADRs manifesting in skin reactions. This study also reveals rare cutaneous ADRs
experienced by Malaysian children under the age of 2, which constitutes a crucial cause
of harm among children.
Keywords: spontaneous adverse drug reactions, pediatric, pharmacovigilance, system organ class, patient
safety, medication safety, allergic skin reaction
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INTRODUCTION
Drug safety in children is major health concern as systematic
reviews have shown a high reporting of adverse drug reactions
(ADRs) in children. Almost one in ten children in hospital
will experience an ADR, 12% of which are serious (Clavenna
and Bonati, 2009). Children are more vulnerable than adults
as their physiological characteristics are still developing. The
pharmacokinetic and pharmacodynamic parameters in children,
particularly neonates and infants, change continuously due to
physical changes (height and weight) and maturation of renal
functions and enzyme systems (Anderson, 2002).
Randomized controlled trials (RCTs) are less effective in
detecting ADRs and offer limited safety information, as certain
vulnerable populations such as pediatric and geriatric patients
are often underrepresented in such trials (Smyth and Weindling,
1999; Nor Aripin et al., 2012). Normally, only mild, moderate or
non-serious ADRs tend to be captured during the development
phase of medicines (Aagaard et al., 2008), whereas the serious
and latent ones may not be captured. In addition, since RCTs
are normally conducted in a controlled environment with
predetermined patient criteria, the severity and staging of the
disease as well as comorbidities may not reflect those found in
routine clinical care, even in the relevant disease. In order to
overcome the shortfalls of RCTs, spontaneous ADR reporting is
a useful source of drug safety information in populations not
routinely tested in RCTs, such as neonates and infants.
A large variety of drugs are prescribed to pediatric patients and
an increased risk of ADRs associated with off-label prescribing
particularly in children under 2 have been reported (Aagaard and
Hansen, 2011; Bellis et al., 2014).
Menniti-Ippolito et al. (2000) conducted a prospective active
monitoring system of ADR in children collected from family
pediatricians in Italy. They concluded that a much higher risk
of developing ADRs in neonate below 1 year old (34.1 per
1000 children) vs. children between 7 and 14 years old (7.4
per 1000 children) (Menniti-Ippolito et al., 2000). Moore et al.
(2002) evaluated the ADR reports submitted to the US Food
and Drug Administration submitted between November 1997
and December 2000 and they found that out of the 243 fatalities
associated with drug therapy annually, 41 and 84% of the
cases occurred during the 1st month of life and the 1st year,
respectively. Meanwhile, Kaguelidou et al. (2016) evaluated ADR
reports of neonates (less than 1 month of life) registered in
the pharmacovigilance database from 1986 to 2012 in France.
More than half of the ADR reports (n = 995) were classified
as serious with a median age of the included patients of 9 days
(Kaguelidou et al., 2016). Although studies have been conducted
on the ADRs in children reported to international and Malaysian
databases, only brief information on the characteristics of ADRs
and drugs in neonates and infants were reported, particularly
among children under 2 years of age (Aagaard et al., 2010b;
Star et al., 2011; Wallerstedt et al., 2011; Aldea et al., 2012;
Barzaga Arencibia et al., 2012). Our previous paper described in
general the ADRs reported in respect to the Malaysian pediatric
population (from birth to 17 years of age) (Rosli et al., 2016).
Thus, the aim of this study is to characterize the ADRs for
children under 2 and to identify the common drugs associated
with ADRs. The current analysis complements our previous
paper and provides an insight into the incidence and type of
ADRs in Malaysian neonates and infants by analyzing ADRs
for children reported to the Malaysian National Centre for
Adverse Drug Reaction. Factors connected to age, gender, type of
reporters, common therapeutic groups, category of ADRs, time
to onset, intensity and outcomes of ADRs were also evaluated.
MATERIALS AND METHODS
Setting
This retrospective study was carried out at National Centre for
ADR Monitoring at the National Pharmaceutical Control Bureau
(NPCB) using ADR data from the national pharmacovigilance
database, QUEST2 System. The QUEST2 system contains
extensive data of spontaneous ADR reports in Malaysia including
those reported by healthcare professionals in government
and/or private health facilities, other health care professionals,
pharmaceutical companies and consumers.
Every ADR reports submitted to the NPCB must include
the following information: patient’s particulars, the suspected
medicine(s), the presumed ADR(s), and the reporter’s details.
Upon receipt of ADR reports, the information is assessed
by trained staff at the NPCB and all findings in each
report, including the causality classification, are discussed in
the Malaysian Adverse Drug Reactions Advisory Committee
(MADRAC) meeting prior to submission to Malaysia’s Drug
Control Authority (DCA) and the WHO Collaborating Centre
in Uppsala (Uppsala Monitoring Centre; WHO-UMC).
For causality assessment, MADRAC utilizes the WHO-UMC
Causality Assessment. The causality between the suspected
drug/s and the reaction/s is assessed as certain, probable, possible,
unlikely, unclassified or unclassifiable. The individual categories
of causality are presented in Supporting Information 1 (SI 1).
In the data retrieved from the QUEST2 system, an ADR
registration number was assigned automatically upon entry into
the database system for record identification. No informed
consent was obtained prior to analysis as the patient information
was already anonymized and de-identified when the data was
entered into the database system.
Approval to conduct this study was obtained from the
National Institute of Health (NIH) and Medical Research
and Ethics Committee (MREC) in the Ministry of Health,
prior to implementation of the study (NMRR-14-1231-21610).
Permission to access to the QUEST2 database was also granted.
Data Extraction
All ADR reports on children under 2 years of age reported
in the QUEST system from 2000 to 2013 were included in
this study. Data on patient’s details (age and gender), type of
reporters, active substance of the medicine, and characteristics
of ADRs (category, time to onset, severity and outcomes) were
extracted from the QUEST2 ADR database into Microsoft R© Excel
files. Onset of ADRs was categorized as: acute (occurring
within 60 min); subacute (occurring within 1–24 h); or latent
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(occurring after 2 days). Onset can be defined as the time from
the start of drug administration to the onset of a reaction.
Severity is defined as the intensity of a specific ADR event
and here is categorized as: mild; moderate; severe; or fatal.
The active substances of the medicines were classified according
to Anatomical Therapeutic Chemical Classification (ATC). The
medicines about which the ADRs were reported are presented
at ATC level 3 to present the large amount of data in a
comprehensive way.
The material comprised all ADR reports on children from
birth to 2 years of age reported to the QUEST system from 2000
to 2013. These ADR reports were then subdivided according
to the age categories based on the International Conference on
Harmonization Guidelines on Clinical Investigation of Medicinal
Products in the Pediatric Population: neonates ≤ 27 days and
infants ≤ 23 months.
The ADRs are grouped and presented according to the
WHO Adverse Reaction Terminology (WHO-ART) system
organ classes (SOCs). For ADRs reporting to WHO-UMC, all
national pharmacovigilance centres may either use WHO-ART
or Medical Dictionary for Regulatory Activities (MedDRA) terms
or codes for reporting to the WHO Global ICSR Database System,
Vigibase. Since, the National Centre for ADR Monitoring in
Malaysia has been using WHO-ART for SOC classification in
their reporting to UMC, the same classification for SOC (WHO-
ART) was used in this study. We counted each report as a
different case with records of more than one term belonging to
the same SOC.
Reports Excluded
In order to enhance the quality of data included in this study,
only ADRs with causality assessed as certain, probable/likely
and possible were analyzed. As one of the National Centers
participating in the WHO Programme for International Drug
Monitoring, NPCB utilized WHO-UMC causality assessment
system for evaluation of ADR reports in Malaysia. ADR reports
relating to non-Malaysian citizens and those that had not been
reviewed by the MADRAC were excluded from the study, as were
reports with age and onset of ADRs not specified. Other ADR
reports that were excluded were reports on food supplements,
traditional and veterinary products, along with ADRs induced by
drug administration to mothers.
Statistics
Data on ADRs according to gender, type of reporters, therapeutic
groups and category of ADRs were described as frequencies and
percentages. The analysis was undertaken using Microsoft Excel
2013 and IBM SPSS Version 19.
RESULTS
Characterization of ADR Reports
From 2000 to 2013, NPCB received a total of 11,932 reports on
children from various healthcare facilities in Malaysia. Of that
volume, approximately 14.0% (n = 1667) of the ADRs reported
were related to children under 2 years old.
The following reports were excluded from the study: Age
group > 2 years old (n = 10099); ADRs with causality evaluated
as neither certain, possible nor probable (n = 20); ADRs due to
drug administration to the mother (n= 106); non-citizen (n= 2);
non-drug products (n = 38); reports with no information on
ADR onset (n = 172); and miscellaneous/others (n = 588). After
exclusion criteria, only 907 ADR reports (neonates, n = 109;
infants, n= 798) remained for analysis (see Figure 1).
In the reports where the gender was known, 57.2% (n = 519)
concerned boys. More than 90% of the reports were sent by
healthcare providers in government health facilities. Most of the
reports were sent by pharmacists (n = 466, 51.4%), followed by
doctors (n = 351, 38.7%). The majority of the reports (n = 610,
67.3%) document one ADR per report, followed by two ADRs
per report (n = 210, 23.2%) and three ADRs per report (n = 71,
7.8%).
System Organ Class
Table 1 illustrates the System Organ Class for ADR reports
received for children under 2 years old. From 907 ADR reports,
there were 1312 types of ADRs reported, mainly Skin Appendage
Disorders (60.1%) and Body as a Whole – General Disorders
(10.1%). Other ADRs reported were Gastrointestinal System
Disorders (6.0%) and Respiratory System Disorders (5.1%). The
most common preferred terms reported were rash (n = 215),
maculopapular rash (n= 206), urticaria (n= 169), erythematous
rash (n= 76), and pruritus (n= 58).
Anatomical Therapeutic Chemical
Classifications
Anti-infectives for Systemic Use (61.9%) was the most
common therapeutic group reported for ADRs in
children below 2 years old. As shown in Table 2, other
common therapeutic groups were for the Nervous System
(15.6%), Respiratory System (6.8%), Alimentary Tract and
Metabolism (4.2%), and Sensory Organs (3.9%). ADR reports
related to the top three therapeutic groups were further
analyzed according to onset, intensity and outcomes of
ADRs.
Antibacterials for Systemic Use contributed the highest
number of ADRs among the antiinfective agents. Penicillin
(30.3%) and other β-Lactam Antibacterials (13.6%) were
the most frequent agents reported for ADRs. The others
were: Macrolides, Lincosamides, and Streptogramins (6.0%);
Aminoglycosides Antibacterials (3.5%); Other Antibacterials
(3.3%); and Sulphonamides and Trimethoprim (1.7%). Antivirals
for Systemic Use that involved Direct Acting Antivirals (2.3%)
were also among agents that were repeatedly reported for ADRs.
For the Nervous System, the reports received were mainly
related to Analgesics, namely Other Analgesics and Antipyretics
(10.5%). Other common agents for the Nervous System
belonged to Antiepileptics (2.9%). For the Respiratory System,
Antihistamines for Systemic Use (1.5%), Adrenergics for
Systemic Use (1.4%), and Other Systemic Drugs for Obstructive
Airway Diseases (1.1%) were often reported for ADRs in this
study.
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FIGURE 1 | Flow chart of methodology and adverse drug reaction (ADR) reports included in the present study.
Onset, Intensity, and Outcomes of ADRs
The onset and the intensity of ADRs related to the three common
therapeutic groups with frequently reported pharmacological
groups are listed in Table 3. The majority of ADRs induced
by Anti-infectives for Systemic Use were subacute reactions,
occurring within 24 h after drug exposure, except for the Other
Antibacterials group, where mainly acute reactions occurred,
within 1 h of drug exposure. A high proportion of ADRs were
classified as mild and moderate whilst there were a small number
of severe ADRs.
Similar to Anti-infectives for Systemic Use, the majority
of ADRs related to medicines for the Nervous System and
Respiratory System were subacute reactions, with a high
proportion of mild and moderate ADRs. Only three drugs were
continued despite ADRs and no rechallenge was performed in the
majority of cases after ADRs developed.
The majority of ADRs observed in children under 2 years old
did not result in sequelae. However, at the time of reporting, a
high number of children with ADRs had not yet recovered with
a small number of ADRs cases had recovered but with sequelae.
Only one ADR had a fatal outcome.
Common Drugs Associated with ADRs
Drugs commonly reported for ADRs in children are summarized
in Table 4. A drug was considered common when the number of
ADR reports received for that particular drug was more than 10
and only ADR SOCs with more than 10 cases were included. As
shown in the table below, Antibacterials for Systemic Use such as
Penicillin (n = 93), Ampicillin (n = 56), Amoxicillin (n = 51),
Cloxacillin (n = 43), and Cefuroxime (n = 51) were often
reported for ADRs in neonates and infants. Most of the ADRs
associated with these drugs were skin reactions. Other frequently
reported drugs were Paracetamol (n = 93), which induced skin
reactions, and Cyclopentolate/Phenylephrine (n = 19) which
induced apnoea.
Cutaneous ADRs Reported in Children
In this study, the cutaneous ADRs that were frequently reported
were erythema multiforme (n = 10) and Stevens–Johnson
Syndrome (n = 10). For erythema multiforme, amoxicillin
(n = 3), erythromycin (n = 2) and paracetamol (n = 2)
were among the contributing agents, whilst for Stevens–Johnson
Syndrome, amoxicillin/clavulanate (n = 3), carbamazepine
(n = 3), and sulfamethoxazole/trimoxazole (n = 2) were among
the drugs reported. The lists of selected cutaneous ADRs detected
in this study are summarized in Table 5.
DISCUSSION
Previous studies have confirmed that neonates and infants have a
higher risk of developing ADRs than other populations (Menniti-
Ippolito et al., 2000; Clavenna and Bonati, 2009; Alomar, 2014).
This current study revealed a low reporting of ADRs in this age
group. This is probably due to under-reporting, as the proportion
of ADRs for Malaysian children under 2 years of age was lower
than that reported to WHO VigiBase (Rosli et al., 2016).
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TABLE 1 | System organ class for children below 2 years old.
System organ class Neonates Infants Total
Skin and Appendages Disorders 60 729 789
Body as a Whole General Disorders 8 124 132
Gastrointestinal System Disorders 8 71 79
Respiratory System Disorders 12 55 67
Urinary System Disorders 12 30 42
Central and Peripheral Nervous System Disorders 8 33 41
Cardiovascular Disorders, General 10 25 35
Heart Rate and Rhythm Disorders 4 16 20
Platelet, Bleeding and Clotting Disorders 6 11 17
Liver and Biliary System Disorders 0 15 15
Neonatal and Infancy Disorders 12 3 15
Psychiatric Disorders 3 12 15
Vascular (Extracardiac) Disorders 0 13 13
Vision Disorders 0 10 10
Application Site Disorders 2 4 6
Metabolic and Nutritional Disorders 1 4 5
Endocrine Disorders 1 1 2
Red Blood Cell Disorders 1 2 3
White Cell and Reticuloendothelial system disorders 1 2 3
Reproductive Disorders, Female 0 1 1
Resistance Mechanism Disorders 1 0 1
Secondary Terms Events 1 0 1
TOTAL 151 1161 1312
TABLE 2 | Therapeutic groups reported for ADRs in children below 2 years
old.
ATC Level 1 Neonates Infants Total
Anti-infectives for Systemic Use 55 506 561
Nervous System 10 131 141
Respiratory System 13 43 56
Alimentary Tract and Metabolism 7 31 38
Sensory Organs 5 30 35
Cardiovascular System 9 7 16
Musculo-skeletal System 3 16 19
Blood and Blood Forming Organs 3 8 11
Dermatologicals 2 7 9
Systemic Hormonal Preparations, Excl.
Sex Hormones and Insulins
0 7 7
Antineoplastic and Immunomodulating
Agents
2 4 6
Various 0 5 5
Antiparasitics Products, Insecticides
and Repellents
0 3 3
TOTAL 109 798 907
Apart from age, being female has been postulated as one of
the risk factors of developing ADRs (Smyth et al., 2012). The
biological differences in term of anatomy and physiology in males
and females significantly affects the way the body deals with
drugs by altering their pharmacokinetics and pharmacodynamics
(Alomar, 2014). A systematic review of ADRs in children
discovered that out of 19 studies evaluated, 10 considered gender
as a risk factor and females were more likely to have an
ADR (Smyth et al., 2012). On the other hand, a multicentre
cohort study involving hospitalized pediatrics from general
medical ward from hospitals in five countries, including Malaysia,
discovered that gender was not significantly associated with
ADRs (Rashed et al., 2012b). The same findings were reported
by other studies, which reported a similar proportion of ADR
reports for males and females. Even so, in these studies there was
no information divided by gender on the proportion of ADRs
for specific age groups, namely neonates and infants (Aagaard
et al., 2010a,b; Aldea et al., 2012). In the current study, the higher
proportion of ADRs in males were most likely contributed by the
higher crude birth rate per 1000 population for males than for
females in Malaysia during the study period (Ministry of Health
Malaysia, 2012, 2015).
In Malaysia, ADR reporting is mainly done by healthcare
personnel from government health facilities, with pharmacists
(51.4%) being the main reporters. This is in agreement with
a study by Le et al. (2006). Our current study reveals that
pharmacists in Malaysia are actively reporting ADRs, which
is different in Denmark (Aagaard et al., 2010a,b). The high
number of reports submitted by pharmacists are in tandem
with the increase in pharmacists working in public hospitals
since 2009, because the Malaysian Ministry of Health introduced
a requirement for pharmacists to complete stipulated years of
compulsory service in public sector before they can register
with the Pharmacy Board of Malaysia (Hadi and Ming,
2011). Besides setting ADR reporting as one of the main key
performance indicators in the Ministry, the initiatives taken
by the NPCB in promoting ADRs reporting in Malaysia has
successfully boosted the number of ADRs being reported. The
Pharmaceutical Services Division at the Ministry of Health, which
is responsible for planning and controlling all activities related to
pharmacy services in Malaysia, has incorporated ADR reporting
in the pharmacist training modules. Every pharmacy candidate
completes these modules during their compulsory training to
become a registered pharmacist. However, while these initiatives
have positively improved the ADR reporting culture in the
government health facilities, it has only had a minimal effect
on the private health facilities, as a very low number of ADR
reports are received from these latter facilities (Rosli et al., 2016).
Meanwhile, studies have shown that approximately 60% of the
participating general practitioners have unsatisfactory knowledge
on how to report an ADR (Agarwal et al., 2013). The same
study also pointed out that, at a result of not knowing how to
submit an ADR report, up to 73% of the participating general
practitioners reported an unsatisfactory attitude toward ADR
reporting (Agarwal et al., 2013).
In the general child population, as documented by other
studies, the largest share of ADR SOCs reported was Skin
Appendage Disorders (60.1%) (Morales-Olivas et al., 2000;
Clavenna and Bonati, 2009; Star et al., 2011; Gallo et al., 2012;
Rashed et al., 2012a). A study by Star et al. (2011) found that
ADRs related to skin reactions were more frequently seen in
children than in adults. One of the underlying causes is the
skin physiology of children, especially neonates and infants,
as humans are born with partially mature and functionally
developing epidermises. Consequently, the epidermal barrier
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TABLE 3 | Onset and intensity of ADRs related to commonly reported pharmacological groups in children below 2 years old.
Type of ADR (onset) Type of ADR (intensity)
Reported pharmacological group Number of cases Acute Subacute Latent Mild Moderate Severe Unknown
ANTI-INFECTIVES FOR SYSTEMIC USE
Antibacterials for Systemic Use
β-Lactam Antibacterials, Penicillins 275 45 163 67 147 112 14 2
Other β-Lactam Antibacterials 123 18 80 25 62 46 11 4
Macrolides, Lincosamides and Streptogramins 54 5 39 10 29 22 3 0
Other Antibacterials 30 13 8 9 12 15 3 0
Aminoglycoside Antibacterials 32 8 11 13 12 14 6 0
Sulfonamides and Trimethoprim 15 1 9 5 5 8 2 0
Antivirals for Systemic Use
Direct Acting Antivirals 21 5 13 3 7 12 2 0
NERVOUS SYSTEM
Antiepileptics 26 6 9 11 10 10 6 0
Other Analgesics and Antipyretics 95 26 58 11 50 39 4 2
RESPIRATORY SYSTEM
Adrenergics for Systemic Use 13 4 7 2 4 7 2 0
Antihistamines for Systemic Use 14 3 9 2 2 5 7 0
Other Systemic Drugs for Obstructive Airway Diseases 10 0 5 5 3 1 3 3
Adrenergics Inhalants 8 3 5 0 5 3 0 0
TABLE 4 | Common drugs associated with ADRs in children below 2 years old.
Common drugs ADR reports Most common preferred terms
J01 Antibacterials for Systemic Use
J01C β-Lactam Antibacterials, Penicillins
Penicillin 93 Rash Maculopapular (n = 36), Rash (n = 25), Urticaria (n = 21), Rash
Erythematous (n = 13), Pruritus (n = 12)
Ampicillin 56 Rash (n = 16), Rash Maculopapular (n = 18), Urticaria (n = 15)
Amoxicillin 51 Rash (n = 17), Rash Maculopapular (n = 15), Urticaria (n = 12)
Cloxacillin 43 Rash Maculopapular (n = 14), Rash (n = 12)
J01D Other β-Lactam Antibacterials
Cefuroxime 51 Rash (n = 18), Urticaria (n = 15), Rash Maculopapular (n = 10)
J01F Macrolides, Lincosamides and Streptogramins
Erythromycin 39 Rash Maculopapular (n = 12), Rash (n = 10)
N02 Analgesics
N02B Other Analgesics and Antipyretics
Paracetamol 93 Rash (n = 31), Urticaria (n = 19), Rash Maculopapular (n = 14)
S01 Opthalmologicals
S01F Mydriatics and Cycloplegics
Cyclopentolate/Phenylephrine 19 Apnoea (n = 12)
TABLE 5 | Selected cutaneous ADRs reported in children below 2 years old.
SOC (WHO-ART CLASSIFICATION) TOTAL SUSPECTED DRUGS
Erythema Multiforme 10 Amoxicillin (n = 3), Ampicillin (n = 1), Cloxacillin (n = 1), Erythromycin (n = 2), Paracetamol (n = 2) Penicillin (n = 1)
Steven–Johnson Syndrome 10 Amoxycilin/clavulanate (n = 3), Carbamazepine (n = 3), Morphine (n = 1), Phenobarbitone (n = 1),
sulfamethoxazole/Trimethoprim (n = 2),
Fixed Drug Eruption 1 Paracetamol (n = 1)
Epidermal Necrolysis 1 Amoxicillin/Clavulanate (n = 1)
function is compromised, leaving the skin more permeable and
vulnerable to chemical and microbial aggressions and skin disease
in the first 2 years of someone’s life (Stamatas et al., 2011).
In general, the therapeutic groups that have been linked to
ADRs were not significantly different among studies conducted
in children (Morales-Olivas et al., 2000; Aagaard et al., 2010b;
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Star et al., 2011; Aldea et al., 2012). Nevertheless, the sub-
groups were different due to changes in prescribing practices
for some therapeutic groups over time and distinct drug
prescribing trends among countries or regions (Aagaard et al.,
2010a). In this study, it has been shown that Antibacterials
for Systemic Use were the most common agents reported for
ADRs. In a multicenter prospective cohort study of hospitalized
children involving five countries, including Malaysia, similar
findings were observed by Rashed et al. (2012a). A huge
number of Antibacterials for Systemic Use were prescribed
in the general pediatric population and a higher number of
ADRs were reported for agents from this therapeutic group
(Clavenna and Bonati, 2009; Priyadharsini et al., 2011; Barzaga
Arencibia et al., 2012; Gallo et al., 2012; Rashed et al., 2012a).
Due to the issue of antibiotic resistance, often multiple types
of antibiotics and broad spectrum antibiotics at high doses
were used for neonatal infection (Manan et al., 2016). In
the current study, the most commonly involved antibiotics
in the reported ADRs were β-lactam and Macrolides, which
is consistent with findings reported in Italy (Menniti-Ippolito
et al., 2000) and Singapore (Kidon and See, 2004). These
antibiotics were associated with ADRs related to skin reactions,
which is also in parallel with the findings of other studies
reporting ADRs from the national pharmacovigilance databases
in Denmark (Aagaard et al., 2010b), India (Priyadharsini
et al., 2011), and Iran (Khotaei et al., 2008). This study
and other studies have shown that ADRs resulting from the
use of β-lactam antibiotics are usually mild, with a small
proportion of severe reactions (Morales-Olivas et al., 2000;
Clarkson and Choonara, 2002; Moore et al., 2002; Rashed
et al., 2012a; Li et al., 2014). The ADRs observed in children
were mild, and the majority of the ADRs did not lead to
sequelae.
Other than antibiotics, mydriatic eye drop (cyclopentolate
and phenylephrine) is among drugs that are commonly
reported for ADRs. Cyclopentolate and phenylephrine eye
drops are rarely absorbed to systemic circulation but serious
side effect like apnoea, tachycardia, rash, feeding intolerance,
discomfort, gastric dilatation, and ileus has been reported in
some cases (Knight, 1994; Sarici et al., 2001; Ozgun et al.,
2014). Mydriatic eye drops are normally applied prior to
routine eye examination for retinopathy of prematurity (ROP)
screening in premature infants. Early detection of ROP is
deemed crucial as it can leads to vision impairment and
blindness if left untreated (Fierson et al., 2013). In this study,
12 cases of apnoea were observed after application of these
agents.
Although hypersensitivity reactions are rare in infants, they
do happen in this population, normally manifested as cutaneous
ADRs (Carder, 2005). It is already known that systemic
antibiotics and anticonvulsants are the major cause of cutaneous
ADRs (Morales-Olivas et al., 2000; Choon and Lai, 2012; Diaz and
Ciurea, 2012; Lin et al., 2014). In this study, there were 10 cases
of erythema multiforme induced by amoxicillin, erythromycin
and paracetamol. Erythema multiforme is a reactive eruption
on the skin and mucous membranes characterized by well-
demarcated, targetoid, erythematous plaques or patches that
develop a dusky or bullous center within several days. The
majority of erythema multiforme cases have been reported with
multiple drugs including β-lactam, macrolides, aminoglycosides,
glycopeptides and other antibiotics (Diaz and Ciurea, 2012;
Sokumbi and Wetter, 2012). For paracetamol, cutaneous adverse
reactions to standard dosages are quite rare and only a
few cases of erythema multiforme have been reported with
the use of paracetamol. In the current study only two
cases of erythema multiforme related to paracetamol were
reported.
On the other hand, there were ten cases of Stevens–
Johnson Syndrome seen in this study. This ADR has been
reported with amoxicillin/clavulanate, carbamazepine and
sulfamethoxazole/trimoxazole. Stevens-Johnson Syndrome is a
serious cutaneous eruption defined by extensive exfoliation and
mucosal membrane involvement. Like erythema multiforme,
Stevens–Johnson Syndrome can be induced by many drugs,
such as sulfamethoxazole/trimethoprim and other sulphonamide
antibiotics, aminopenicillins, cephalosporins, quinolones,
carbamazepine, phenytoin, and phenobarbital (Harr and French,
2010; Diaz and Ciurea, 2012).
This study presents the ADR data from the QUEST2
pharmacovigilance database reported for Malaysian children
under 2 years old and only reports the reporting of ADRs
in children, characteristics of ADRs (category, onset, intensity,
outcomes), and the most frequently reported drugs with their
common clinical presentation of ADRs. In this study, detailed
management of the reaction was not studied since some of this
data were not readily available. Furthermore, the relationship
between the use of off-labeled drugs and the occurrence of ADRs
was not studied since the majority of the ADR reporting did not
indicate that.
Current literature indicated a relatively sparse spontaneous
reporting of pediatric ADRs in Malaysia. Active surveillance
studies should be conducted in the Malaysian pediatric
population since our findings as well as studies reported by
Rashed et al. (2012a,b) have shown relatively high rates of ADRs
experienced by pediatric inpatients in Malaysia. Future studies
monitoring ADRs should be undertaken in a real hospital setting
involving neonates and children under 2 years of age, as this
study observed only a small number of ADRs for this group
being reported to the national pharmacovigilance system. It is
vital as other literature reported prominent ADR reporting in this
population.
The data is derived entirely from the Malaysian ADR
spontaneous reporting database. Underreporting of ADRs is one
of the main limitations of this system, as proven by a review
which discovered a lower ADR reported from studies using
ADR data from the pharmacovigilance database than studies
using a chart review (Hazell and Shakir, 2006; Aagaard et al.,
2010a).
CONCLUSION
The data from the current study reveals that ADRs in children
under 2 years old are mainly related to antibiotics, which could be
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a reflection of the common usage of antibiotics in this population
group.
A large proportion of ADRs in children under 2 years old was
mainly induced by drugs from the antibacterial for systemic use
group, and most of the ADRs were skin reactions. This study also
reveals rare cutaneous ADRs experienced by Malaysian children
younger than 2 years old, which constitutes a crucial cause of
harm in children.
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